Friday, July 10, 2026

pharma · Alzheimer Disease · Pulmonary Fibrosis

Shanghai University of

Shanghai University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Alzheimer Disease, Pulmonary Fibrosis, RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, Chemotherapy, Adjuvant, Neoplasm

Shanghai, China, CN HQ
6 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Shanghai, China, CN
Employees
6
Programs
24
Drugs
33
Patents
0
Clinical program

9MW3811 injection

Phase 1 · small molecule · Pulmonary Fibrosis

9MW3811 injection for Pulmonary Fibrosis is a Phase 1 program (small_molecule) at Shanghai University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).

Internal code 9MW3811-2022-CP101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Shanghai University of Traditional Chinese Medicine
Phase
Phase 1
Modality
small_molecule
Indication
Pulmonary Fibrosis
Status
completed
Trials
1

Clinical trials